You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – A new genomic, immune profiling, and imaging study suggests there may multiple signatures for predicting response to a PARP inhibitor and checkpoint immunotherapy drug combination in advanced ovarian cancer patients.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.
M2Gen’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments.